{"id":3661,"date":"2014-04-01T00:22:36","date_gmt":"2014-04-01T00:22:36","guid":{"rendered":"http:\/\/www.glycorx.com\/?page_id=3661"},"modified":"2023-03-13T23:14:35","modified_gmt":"2023-03-13T23:14:35","slug":"research","status":"publish","type":"page","link":"https:\/\/glycomantra.com\/sample\/research\/","title":{"rendered":"Research"},"content":{"rendered":"<section class=\"wpb-content-wrapper\">[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132654161{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text]\n<h1><span style=\"color: #2684c4;\">Novel Therapeutics:<\/span><\/h1>\n<p>Our proprietary approach is groundbreaking. We leverage carbohydrate functionality which makes our biologic glycoprotein drugs <strong><u>First-in-Class<\/u><\/strong>. The drug target is Galectin-3 (a beta-galactoside-binding lectin), known to be involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and type 2 diabetes.<\/p>\n<p><strong>Our Novel Products Break <\/strong><strong>Galectin-3&#8217;s Natural Affinity:<\/strong><\/p>\n<p>The interactions of Galectin-3 and its endogenous ligands are typically strong \u2013 in the nanomolar range. So, it\u2019s important to break the Galectin-3\u2019s natural interactions for the development of a successful Galectin-3 targeted therapy. Our high affinity Galectin-3 antagonists (GM100 series, patent awarded) are more powerful than its natural ligands as they bind Galectin-3 with picomolar afiinity. As such, our drug candidates act as decoys in the treatment of cancers and metabolic diseases.<\/p>\n<p>Our GM100 series drugs are:<\/p>\n<ul>\n<li>Exceptionally potent with <strong>picomolar<\/strong> affinity (100X stronger than a typical antibody). Our products are unique as they outcompete Galectin-3&#8217;s natural affinity to its endogenous ligands.<\/li>\n<li><strong>No off-target<\/strong> effects observed in animal models<\/li>\n<li><strong>Non-immunogenic<\/strong>.<\/li>\n<li><strong>Favorable pharmacokinetics<\/strong><\/li>\n<li><strong>High therapeutic index<\/strong><\/li>\n<li><strong>Consistent preparation<\/strong> of recombinant glycoprotein<\/li>\n<li><strong>Scalable<\/strong><\/li>\n<\/ul>\n<p>Our current indications for the GM100 series drugs are:<\/p>\n<ul>\n<li><strong>Drug resistant mCRPC (metastatic castration-resistant prostate cancer)<\/strong><\/li>\n<li><strong>NASH (Non-alcoholic steatohepatitis)<\/strong><\/li>\n<li><strong>Type 2 diabetes<\/strong><\/li>\n<\/ul>\n<h1><\/h1>\n[\/vc_column_text]<div class=\"vcex-spacing wpex-w-100 wpex-clear\"><\/div><a href=\"http:\/\/www.glycorx.com\/?page_id=3530\" class=\"vcex-button theme-button graphical blue large align-left inline  wpb_animate_when_almost_visible wpb_appear appear\" style=\"border-radius:3px;\" title=\"Contact Us\" rel=\"none\"><span class=\"vcex-button-inner theme-button-inner\">Contact us<\/span><\/a> [\/vc_column][\/vc_row]\n<\/section>","protected":false},"excerpt":{"rendered":"<p>[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132654161{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Novel Therapeutics: Our proprietary approach is groundbreaking. We leverage carbohydrate functionality which makes our biologic glycoprotein drugs First-in-Class. The drug target is Galectin-3 (a beta-galactoside-binding lectin), known to be involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Research - https:\/\/glycomantra.com\/sample<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/glycomantra.com\/sample\/research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Research - https:\/\/glycomantra.com\/sample\" \/>\n<meta property=\"og:description\" content=\"[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132654161{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Novel Therapeutics: Our proprietary approach is groundbreaking. We leverage carbohydrate functionality which makes our biologic glycoprotein drugs First-in-Class. The drug target is Galectin-3 (a beta-galactoside-binding lectin), known to be involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/glycomantra.com\/sample\/research\/\" \/>\n<meta property=\"og:site_name\" content=\"https:\/\/glycomantra.com\/sample\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-13T23:14:35+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/glycomantra.com\/sample\/research\/\",\"url\":\"https:\/\/glycomantra.com\/sample\/research\/\",\"name\":\"Research - https:\/\/glycomantra.com\/sample\",\"isPartOf\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#website\"},\"datePublished\":\"2014-04-01T00:22:36+00:00\",\"dateModified\":\"2023-03-13T23:14:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/research\/#breadcrumb\"},\"inLanguage\":\"en\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/glycomantra.com\/sample\/research\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/glycomantra.com\/sample\/research\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/glycomantra.com\/sample\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#website\",\"url\":\"https:\/\/glycomantra.com\/sample\/\",\"name\":\"https:\/\/glycomantra.com\/sample\",\"description\":\"Glycomantra\",\"publisher\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/glycomantra.com\/sample\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#organization\",\"name\":\"Glycomantra\",\"url\":\"https:\/\/glycomantra.com\/sample\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en\",\"@id\":\"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png\",\"contentUrl\":\"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png\",\"width\":72,\"height\":72,\"caption\":\"Glycomantra\"},\"image\":{\"@id\":\"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Research - https:\/\/glycomantra.com\/sample","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/glycomantra.com\/sample\/research\/","og_locale":"en_US","og_type":"article","og_title":"Research - https:\/\/glycomantra.com\/sample","og_description":"[vc_row css_animation=&#8221;appear&#8221; center_row=&#8221;yes&#8221; bg_style=&#8221;stretch&#8221; video_bg_overlay=&#8221;none&#8221; css=&#8221;.vc_custom_1622132654161{padding-top: 0px !important;padding-bottom: 0px !important;}&#8221;][vc_column][vc_column_text] Novel Therapeutics: Our proprietary approach is groundbreaking. We leverage carbohydrate functionality which makes our biologic glycoprotein drugs First-in-Class. The drug target is Galectin-3 (a beta-galactoside-binding lectin), known to be involved in many diseases that are associated with chronic inflammation such as cancer, organ fibrosis, and&hellip;","og_url":"https:\/\/glycomantra.com\/sample\/research\/","og_site_name":"https:\/\/glycomantra.com\/sample","article_modified_time":"2023-03-13T23:14:35+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/glycomantra.com\/sample\/research\/","url":"https:\/\/glycomantra.com\/sample\/research\/","name":"Research - https:\/\/glycomantra.com\/sample","isPartOf":{"@id":"https:\/\/glycomantra.com\/sample\/#website"},"datePublished":"2014-04-01T00:22:36+00:00","dateModified":"2023-03-13T23:14:35+00:00","breadcrumb":{"@id":"https:\/\/glycomantra.com\/sample\/research\/#breadcrumb"},"inLanguage":"en","potentialAction":[{"@type":"ReadAction","target":["https:\/\/glycomantra.com\/sample\/research\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/glycomantra.com\/sample\/research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/glycomantra.com\/sample\/"},{"@type":"ListItem","position":2,"name":"Research"}]},{"@type":"WebSite","@id":"https:\/\/glycomantra.com\/sample\/#website","url":"https:\/\/glycomantra.com\/sample\/","name":"https:\/\/glycomantra.com\/sample","description":"Glycomantra","publisher":{"@id":"https:\/\/glycomantra.com\/sample\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/glycomantra.com\/sample\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en"},{"@type":"Organization","@id":"https:\/\/glycomantra.com\/sample\/#organization","name":"Glycomantra","url":"https:\/\/glycomantra.com\/sample\/","logo":{"@type":"ImageObject","inLanguage":"en","@id":"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/","url":"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png","contentUrl":"http:\/\/www.glycorx.com\/wp-content\/uploads\/2014\/03\/final-logo-72.png","width":72,"height":72,"caption":"Glycomantra"},"image":{"@id":"https:\/\/glycomantra.com\/sample\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/3661"}],"collection":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/comments?post=3661"}],"version-history":[{"count":34,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/3661\/revisions"}],"predecessor-version":[{"id":4214,"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/pages\/3661\/revisions\/4214"}],"wp:attachment":[{"href":"https:\/\/glycomantra.com\/sample\/wp-json\/wp\/v2\/media?parent=3661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}